World Drug Prices Up 10% In January-June 1995

10 September 1995

Sales of pharmaceutical products through retail outlets in the world's 10 leading markets increased 10% to reach a total value of $69.11 billion in the six months from January to June 1995, compared with the like, year-earlier period, according to the latest figures published last week by IMS International.

North American sales grew 11% during the period to a total of $28.78 billion; this category consisted of 11% growth for the US market to a value of just over $27 billion, and growth of 6% for the Canadian market, which reached $1.74 billion. The Japanese market also reported sales up 11% in the six months, to reach a total of $13.49 billion, while for Europe's top seven markets, an average sales increase of 8% was reported, to $26.83 billion.

Spain Sees Biggest Single Market Growth The biggest rise by individual country during the period was reported for Spain, where retail pharmacy sales advanced 13% to $2.36 billion, followed by germany and the UK, both rising 9% to $8.28 billion and just over $3 billion, respectively. Next among the European markets were France and the Netherlands, both showing growth of 7% to reach $7.28 billion and just over $1 billion respectively. The Belgian market advanced 6% during the period to $980 million, and Italy reported a 3% increase, to $3.81 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight